Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone Disease

Extended CRYSVITA therapy significantly improves pain, stiffness, fatigue and physical and ambulatory function compared to baseline after 96 weeks TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) today announced the publication of...

Full "IntellAsia: Resources" article